NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
Clinical Trials
135 trialsNCT03334305 2026-01-29
ACTION
University of Florida
Phase 1 Terminated
NCT06193174 2026-01-22
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
University of Alabama at Birmingham
Phase 1 Terminated
NCT05267106 2025-12-30
FIGHT-209
Incyte Corporation
Phase 2 Terminated
NCT04424966 2025-10-24
Infigratinib in Recurrent High-Grade Glioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Terminated
NCT03868943 2025-10-21
JAZZ
Wake Forest University Health Sciences
Phase 2 Terminated
NCT00897286 2025-10-20
Study of Stored Tumor Samples in Young Patients With Brain Tumors
St. Jude Children's Research Hospital
Terminated
NCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
NCT05189366 2025-10-07
SOPHNEURO
Institut Cancerologie de l'Ouest
Phase NA Terminated
NCT06270082 2025-09-19
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Ikena Oncology
Phase 1 Terminated
NCT04762602 2025-09-16
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Hutchmed
Phase 1 Terminated
NCT03149575 2025-09-04
STAR-3
Kintara Therapeutics, Inc.
Phase 3 Terminated
NCT03330197 2025-08-12
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
Alaunos Therapeutics
Phase 1/2 Terminated
NCT03018288 2025-08-08
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT06038760 2025-07-30
PEAR-GLIO
Ourotech, Inc.
Terminated
NCT03295396 2025-07-28
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT05297864 2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2 Terminated
NCT01324635 2025-05-02
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
Thomas Jefferson University
Phase 1 Terminated
NCT03095248 2025-04-22
SEL-TH-1601
Children's Hospital Medical Center, Cincinnati
Phase 2 Terminated
NCT03690869 2025-04-08
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT05737212 2025-02-21
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
Dawonmedax Co., Ltd.
Phase 1/2 Terminated
NCT03416530 2025-02-14
ONC201 in Pediatric H3 K27M Gliomas
Jazz Pharmaceuticals
Phase 1 Terminated
NCT04552756 2025-01-15
SURF-ROGG
University Hospital Schleswig-Holstein
Phase NA Terminated
NCT01743950 2025-01-08
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
University of Wisconsin, Madison
Phase 2 Terminated
NCT05500508 2024-12-24
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Phase 1/2 Terminated
NCT04404569 2024-12-20
ETERNITI
Bexion Pharmaceuticals, Inc.
Phase 1 Terminated
NCT04771897 2024-12-20
KONQUER
Bexion Pharmaceuticals, Inc.
Phase 1 Terminated
NCT02372409 2024-11-01
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Washington University School of Medicine
Phase 2 Terminated
NCT03973918 2024-10-31
BRAF
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT01246869 2024-10-01
Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water
University of Utah
Phase 1 Terminated
NCT03796273 2024-09-19
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
Wake Forest University Health Sciences
Phase EARLY_PHASE1 Terminated
NCT02924038 2024-06-14
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
University of California, San Francisco
Phase 1 Terminated
NCT02386241 2024-04-19
Identification of Genomic Changes in Families Having Multiple Members With Tumors
St. Joseph's Hospital and Medical Center, Phoenix
Terminated
NCT04556929 2024-03-22
EDGE
University of Oxford
Phase NA Terminated
NCT05394558 2023-12-26
AsiDNA
Institut Curie
Phase 1/2 Terminated
NCT02833701 2023-10-24
Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
University of Nebraska
Phase 1 Terminated
NCT02659800 2023-10-06
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT03593993 2023-10-06
A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Terminated
NCT02095353 2023-08-23
Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients
University of Nebraska
Terminated
NCT04608812 2023-08-18
Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
OncoSynergy, Inc.
Phase 1 Terminated
NCT04541225 2023-07-14
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT04650204 2023-06-22
Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy
Mayo Clinic
Phase 4 Terminated
NCT03927274 2023-05-25
Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Terminated
NCT05875935 2023-05-25
ECoG
Ramsay Générale de Santé
Phase NA Terminated
NCT03332355 2023-05-24
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Vanquish Oncology, Inc.
Phase 1 Terminated
NCT03436433 2023-04-13
Seizure Prophylaxis in Patients With Glioma or Brain Metastasis
Duke University
Phase 2 Terminated
NCT04730349 2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT01700569 2023-02-21
FOLAGLI
Institut Cancerologie de l'Ouest
Phase 1 Terminated
NCT01986348 2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT04851834 2022-12-20
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Xennials Therapeutics Australia Pty Ltd
Phase 1/2 Terminated